Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17

Nuvaxovid™ COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 in Europe Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Commission (EC) has approved the expanded conditional marketing authorization (CMA) of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine in the […]

thaipr.net

6 ก.ค. 65
1 1,900 1,901 1,902 1,903 1,904 3,047